Medicus Pharma Ltd. is a clinical stage, multi-strategy holding company, which engages in investing in novel life sciences and bio-technology companies. The company is headquartered in Toronto, Ontario. The company went IPO on 2023-10-11. Its subsidiaries include SkinJect, Inc, and Medicus Pharma Inc. The Company’s wholly owned subsidiary, SkinJect, Inc (SkinJect), is focused on commercializing a novel, non-invasive treatment for basal cell skin cancer using a patented dissolvable microneedle patch to deliver chemotherapeutic agent to eradicate tumor cells. The Company’s wholly owned subsidiaries are focused on the development of a drug delivery system using a dissolvable microneedle array for the treatment of certain skin cancers. The firm investigates opportunities across all therapeutic areas where an unmet need exists for improved patient safety and efficacy. The firm is actively exploring expanding its drug development pipeline through qualified and accretive acquisitions and partnerships.
Dr. Raza Bokhari is the Executive Chairman of Medicus Pharma Ltd, joining the firm since 2023.
What is the price performance of MDCX stock?
The current price of MDCX is $0.3141, it has decreased 5.56% in the last trading day.
What are the primary business themes or industries for Medicus Pharma Ltd?
Medicus Pharma Ltd belongs to Biotechnology industry and the sector is Health Care
What is Medicus Pharma Ltd market cap?
Medicus Pharma Ltd's current market cap is $12.3M
Is Medicus Pharma Ltd a buy, sell, or hold?
According to wall street analysts, 6 analysts have made analyst ratings for Medicus Pharma Ltd, including 2 strong buy, 6 buy, 1 hold, 0 sell, and 2 strong sell